The Prognostic Value of the Systemic Immune-Inflammation Index (SII) and Red Cell Distribution Width (RDW) in Patients with Cervical Cancer Treated Using Radiotherapy

Emilia Staniewska,Karolina Grudzien,Magdalena Stankiewicz,Katarzyna Raczek-Zwierzycka,Justyna Rembak-Szynkiewicz,Zuzanna Nowicka,Rafal Tarnawski,Marcin Miszczyk
DOI: https://doi.org/10.3390/cancers16081542
2024-04-19
Cancers
Abstract:Introduction: There is growing interest in the prognostic value of routinely performed pre-treatment blood test indices, such as the red cell distribution width (RDW) or systemic immune-inflammation index (SII), with the latter combining the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). These indices were shown to be prognostic for survival in some malignancies. The purpose of this study was to evaluate the association between pre-treatment RDW and SII, and overall survival (OS) in patients treated with radiotherapy for primary localised cervical cancer. Material and Methods: This retrospective analysis included patients treated with definitive chemoradiation therapy (CRT) between 2011 and 2017 for histopathologically confirmed FIGO 2018 stage IB2-IVA cervical cancer. Statistical analysis was performed using the Kaplan–Meier method, two-sided log-rank tests, and Cox proportional hazards models, with the Akaike Information Criterion (AIC) serving as a prediction error estimator. Results: The study group included 249 patients with a median age of 57.2 years and a median follow-up of 75.8 months. The majority were diagnosed with squamous cell carcinoma (237, 95.2%) and had FIGO stage III (211, 84.7%). Approximately half of the patients (116; 46.4%) had regional lymph node metastases. Patients with a low RDW (≤13.4%) and low SII (≤986.01) had a significantly longer OS (p = 0.001 and p = 0.002). The RDW remained as an independent prognostic factor in the multivariable model (high vs. low; HR = 2.04; 95% CI: 1.32–3.16; p = 0.001). Including RDW in the model decreased the Akaike Information Criterion from 1028.25 to 1018.15. Conclusions: The RDW is a cheap and widely available index that is simultaneously an independent prognostic factor for survival and could be used to improve pre-treatment prognosis assessments in patients with cervical cancer undergoing CRT. Available data encourage assessing the RDW as a prognostic factor in prospective trials to aid the identification of candidates for treatment escalation.
oncology
What problem does this paper attempt to address?
This paper primarily explores the value of Red Cell Distribution Width (RDW) and Systemic Immune-Inflammation Index (SII) as prognostic indicators in cervical cancer patients undergoing radiotherapy. ### Research Background and Objectives - **Background**: Cervical cancer remains the fourth leading cause of cancer-related deaths among women worldwide. RDW and SII are common hematological indicators, with SII combining the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR). - **Research Objectives**: To evaluate the association between RDW and SII with overall survival (OS) in patients with primary locally advanced cervical cancer undergoing definitive chemoradiotherapy (CRT). ### Research Methods - **Design Type**: Retrospective study. - **Participants**: Included 249 patients who received definitive CRT between 2011 and 2017, with histopathologically confirmed FIGO 2018 stage IB2-IVA cervical cancer. - **Statistical Analysis**: Statistical analysis was performed using the Kaplan-Meier method, two-sided log-rank test, and Cox proportional hazards model, with the Akaike Information Criterion (AIC) used as a predictor error estimator. ### Main Findings - The majority of patients were diagnosed with squamous cell carcinoma (95.2%) and were at FIGO stage III (84.7%). - Patients with RDW ≤13.4% and SII ≤986.01 had significantly longer overall survival (p<0.01). - In the multivariable model, RDW remained an independent prognostic factor (p<0.01). - The model including RDW reduced the AIC from 1028.25 to 1018.15, indicating improved model fit. ### Conclusion - RDW is an inexpensive and easily obtainable index that can serve as an independent prognostic factor to improve pre-treatment assessment in cervical cancer patients undergoing CRT. - The study suggests further evaluation of RDW as a prognostic factor in prospective trials to help identify candidates for treatment escalation.